DGAP-News

Newron announces AGM 2021 result

DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): AGM/EGM Newron announces AGM 2021 result 13.04.2021 / 12:00 The issuer is solely responsible for the content of this announcement. Newron announces AGM 2021 result

Milan, Italy - April 13, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that its shareholders approved the sole motion on the agenda of the AGM 2021 held today, being the approval of the Company's balance sheet as of 31 December 2020 (including related and consequent resolutions).

About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago^(R)/safinamide has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the USA, Australia, Canada, Brazil, Colombia, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron's Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com

For more information
Newron
Stefan Weber - CEO
[phone]
[e-mail]

UK/Europe
Simon Conway/ Natalie Garland-Collins, FTI Consulting
[e-mail]

Switzerland
Valentin Handschin, IRF Reputation
[phone]
[e-mail]

Germany/Europe
Anne Hennecke/Caroline Bergmann, MC Services
[phone]
[e-mail]

USA
Paul Sagan, LaVoieHealthScience
[phone], Ext. 112
[e-mail]

---

13.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

1184059  13.04.2021